Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Wegovy: A higher-dose injectable version specifically approved for chronic weight management in adults and children aged 12 and older with obesity or overweight conditions
Decreased hypothalamic glucagon- like peptide-1 receptor expression in type 2 diabetes patients
Model Your Retatrutide Results Use our free calculator to visualize drug levels and plan your dosing schedule based on clinical trial data
Abbreviations AACE: American Association of Clinical Endocrinology AE: Adverse event CDS: Chinese Diabetes Society DPP-4i: Dipeptidyl peptidase-4 inhibitor ETD: Estimated treatment difference FPG: Fasting plasma glucose GLP-1: Glucagon-like peptide-1 GLP-1RA: Glucagon-like peptide-1 receptor agonist PIONEER: Peptide Innovation for Early Diabetes Treatment SAE: Serious adverse event SF-36v2: 36-item Short Form Health Survey (Acute Version) SMPG: Self-monitored plasma glucose References Sun H, Saeedi P, Karuranga S et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045
US$ 21.24
US$ 29.30
US$ 20.71
01127-3/asset/cb71a1fc-b829-4644-a5d6-f1f235f450bf/main.assets/gr2_lrg.jpg)
![Composite primary outcome in PIONEER 6 [25]. Cumulative incidence plots](https://www.researchgate.net/publication/343772424/figure/fig1/AS:1024481283817472@1621266780897/Composite-primary-outcome-in-PIONEER-6-25-Cumulative-incidence-plots-for-the-primary.png)
